Sanofi (NASDAQ:SNY) Shares Sold by Parsons Capital Management Inc. RI

Parsons Capital Management Inc. RI lowered its position in shares of Sanofi (NASDAQ:SNY) by 6.4% in the second quarter, Holdings Channel reports. The institutional investor owned 13,165 shares of the company’s stock after selling 900 shares during the period. Parsons Capital Management Inc. RI’s holdings in Sanofi were worth $639,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. International Assets Investment Management LLC acquired a new position in Sanofi during the fourth quarter worth $4,704,000. Daiwa Securities Group Inc. increased its stake in Sanofi by 3.4% in the 4th quarter. Daiwa Securities Group Inc. now owns 6,541 shares of the company’s stock valued at $325,000 after purchasing an additional 216 shares in the last quarter. abrdn plc acquired a new stake in Sanofi in the fourth quarter valued at $7,889,000. Grandfield & Dodd LLC increased its position in shares of Sanofi by 1.5% in the fourth quarter. Grandfield & Dodd LLC now owns 381,978 shares of the company’s stock valued at $18,996,000 after buying an additional 5,600 shares in the last quarter. Finally, Cetera Trust Company N.A acquired a new position in Sanofi during the fourth quarter worth about $300,000. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Trading Up 0.5 %

NASDAQ:SNY traded up $0.29 during mid-day trading on Tuesday, reaching $54.81. The company’s stock had a trading volume of 18,831 shares, compared to its average volume of 2,106,420. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The stock has a market cap of $138.82 billion, a P/E ratio of 27.40, a P/E/G ratio of 1.55 and a beta of 0.59. The company’s fifty day simple moving average is $50.41 and its two-hundred day simple moving average is $48.86. Sanofi has a twelve month low of $42.63 and a twelve month high of $55.72.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, July 25th. The company reported $0.93 EPS for the quarter, topping the consensus estimate of $0.88 by $0.05. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The firm had revenue of $10.75 billion during the quarter, compared to analyst estimates of $16.86 billion. During the same quarter in the prior year, the business posted $0.95 earnings per share. Sanofi’s revenue for the quarter was up 7.8% compared to the same quarter last year. On average, equities analysts predict that Sanofi will post 4.18 EPS for the current year.

Analyst Ratings Changes

SNY has been the subject of several recent research reports. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Sunday. Argus boosted their target price on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.